CD274 and neoplasm: A different approach might be the association of OVs with new oncolytic immune-treatments of tumour, such as the immune checkpoint inhibitors aiming cytotoxic T lymphocyte antigen 4 (CTLA-4) and the PD-1/PD-L1 pathway [163].